Eyelid wipe drug for dry eye disease
Raised to date
$9.2M
of $15M offered across 2 Form D filings
IVIEW Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing innovative treatments for ocular diseases. By focusing on unmet medical needs in the ophthalmology sector, the company aims to create effective therapies for conditions including dry eye disease, conjunctivitis, myopia, glaucoma, and presbyopia.
IVIEW stands out with its novel delivery methods and mechanisms of action, particularly its ophthalmic eyelid wipe for dry eye disease, which offers a differentiated approach in treatment.
| Filed | Security | Sold of offered | Filing |
|---|---|---|---|
| Jun 10, 2025 | Equity | $9.2M/ $15M | Form D/A |
| Feb 24, 2025 | Equity | $7.7M/ $15M | Form D/A |
Ocular treatment
IVW-1001 is a novel TRPM8 agonist specifically designed for the treatment of dry eye disease. This innovative product is delivered via an ophthalmic eyelid wipe, ensuring both ease of use and targeted action directly at the affected area.
Built for
Patients suffering from ocular diseases
